524715 and SUNPHARMA Related Headlines
Go Back- At the ASCO® 2026 Annual Meeting, Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT™ (cosibelimab-ipdl)
- Sun Pharma to acquire Organon for $14 per share in $11.75 billion deal
- Sun Pharma signs Definitive Agreement to Acquire Organon
- Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA® (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis
- Sun Pharma Announces the Availability of UNLOXCYT™ (cosibelimab-ipdl) for Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)
- Sun Pharma Announces Jeremy Allen as Vice President, Corporate Affairs for North America
524715 and SUNPHARMA Related Press Releases
Go Back- At the ASCO® 2026 Annual Meeting, Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT™ (cosibelimab-ipdl)
- Sun Pharma signs Definitive Agreement to Acquire Organon
- Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA® (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis
- Sun Pharma Announces the Availability of UNLOXCYT™ (cosibelimab-ipdl) for Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)
- Sun Pharma Announces Jeremy Allen as Vice President, Corporate Affairs for North America
